FDAnews Drug Daily Bulletin

Avastin Touted Over Long Term for NSCLC

A A
Carefully selected patients with non-small cell lung cancer (NSCLC) achieved a median overall survival of 31 months with first-line chemotherapy with bevacizumab, followed by long-term bevacizumab maintenance.
MedPage Today